According to THE SAGE GROUP, Restenosis Remains a Significant and Costly Problem After Endovascular Treatment of Peripheral Artery Disease (PAD)

BEAUFORT, S.C.--(BUSINESS WIRE)--Recent research published by THE SAGE GROUP examined the incidence and cost of restenosis in femoropopliteal disease.

“The cost of restenosis after treatment with percutaneous transluminal angioplasty (PTA) is $364-$728 million,” stated Mary L. Yost, President of THE SAGE GROUP. “New technologies, drug-coated balloons (DCBs) and drug-eluting stents (DES), have decreased restenosis and reduced longer-term revascularization costs.”

“Reflecting higher-priced devices, initial treatment with DCBs and DES costs more. However, with fewer reinterventions, DCB are the most cost-effective treatment followed by DES,” Yost explained.

Yost elaborated on significant factors that affect economic outcomes, “Bailout stenting increases costs in DCB interventions, adding approximately $2,200 to initial procedure costs. The total cost impact depends on the percentage of bailout stenting required. While some studies showed stenting rates below 20%, others found much higher rates of 40% to 60%. Since costs are a key variable in cost-effectiveness analyses, higher bailout stenting rates with DCB procedures adversely impact economic outcomes.”

“Even with the availability of new drug-coated devices, restenosis remains a major, costly problem,” Ms. Yost stated. “This reflects the fact that restenosis is higher in real-world patients than in the populations studied in DCB and DES clinical trials and registries.”

“Approximately, 80% of patients do not meet U.S. clinical device trial inclusion criteria. Consequently, PAD patients with severe critical limb ischemia (CLI) are commonly excluded, as are those with a high percentage of TASC C and D lesions, long total occlusions, severe calcification, extensive popliteal vessel involvement and no runoff vessels,” Yost explained. “These are all factors that increase the risk of restenosis.”

About the Report: Femoropopliteal Disease: Incidence of Restenosis

After Endovascular Revascularization and Review of Cost-Effectiveness Analyses

The report focuses on endovascular treatment of femoropopliteal disease. Incidence of restenosis (CD-TLR) is reviewed by device (PTA, BMS, DES and DCB) for clinical trials and registries. Restenosis is also assessed for real-world patients, long lesions and by disease severity.

Cost-effectiveness studies in the U.S., Germany and the UK are reviewed and analyzed.

Additional information: https://www.thesagegroup.us/reports/femoropopliteal-disease-incidence-of-restenosis-after-endovascular-revascular-revascularization-and-review-of-cost-effectiveness-analyses/.

THE SAGE GROUP, a research and consulting company, specializes in PAD, Intermittent Claudication (IC), CLI and chronic venous disease.

Additional information: www.thesagegroup.us.